Metri Bio just came out of stealth with a $5M pre-seed raise that feels less like an intro and more like a reminder that some problems stay unsolved only because no one built the right tools. Pillar VC led the round with the confidence of a firm that has seen scientist-founded companies change industries before, and Pace Ventures joined with the kind of conviction that says they have been waiting for someone to take endometrial disease seriously at scale. The play here is not subtle. Women’s health has been underfunded for decades, and endometriosis alone hits nearly 190M women worldwide while receiving barely 1% of research dollars outside oncology. When the science runs on scraps, progress is slow. When someone finally brings human relevant biology to the table, everything shifts.
That someone is Dr. Ashley Abel, whose PhD work in Professor Berna Sozen’s lab at Yale built the scientific backbone for Metri Bio. While most of the field kept trying to model a human disease in rodents that do not even menstruate, Dr. Ashley Abel engineered 3D stem cell systems that recreate the embryo maternal interface with precision you cannot ignore. That research was not a side project. It became the blueprint for a platform that models the endometrium using human-only systems, giving the company a way to identify disease drivers that no animal model has ever revealed. The tech is grounded, the biology is clean, and the timing is impeccable. Women’s health funding jumped from 12% of biopharma investment in 2021 to 34% in 2024, and the market for endometriosis therapeutics is projected to climb past $6B by the early 2030s. McKinsey puts the broader commercial potential between $180B and $250B. Numbers like that pull capital toward anyone capable of building real solutions, not repackaged hormonal stopgaps.
Pillar VC saw that before most. Their Frequency Bio program helped shape Dr. Ashley Abel’s entrepreneurial instincts during her doctoral work, and this pre-seed round signals they believe her platform can move the field from symptom management to genuine disease modification. Pace Ventures brings its own edge through Dr. Luka Nićin, who has been vocal about endometriosis being one of the most overlooked frontiers in women’s health. The alignment is tight. A scientific founder with a platform built on human biology, investors who specialize in backing deep research, and a market starving for innovation that respects the scale of the problem.
Metri Bio is early, but early is where the smartest companies make the biggest moves. A $5M raise at pre-seed is not noise. It is a marker that the industry is ready for someone to build therapeutics that finally match the complexity of the endometrium instead of treating it like a footnote.
Startups Startup Funding Early Stage Venture Capital Pre Seed Biotech Healthcare Health Tech Women’s Health Technology Innovation Tech Ecosystem Startup Ecosystem
